Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
October 8, 2024 1:00 PM 5 min read

Deep Dive Into Fortrea Holdings Stock: Analyst Perspectives (12 Ratings)

by Benzinga Insights Benzinga Staff Writer
Follow
FTRE Logo
FTREFortrea Holdings Inc
$11.59-%
Overview

In the preceding three months, 12 analysts have released ratings for Fortrea Holdings (NASDAQ:FTRE), presenting a wide array of perspectives from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.58, a high estimate of $30.00, and a low estimate of $21.00. A decline of 17.32% from the prior average price target is evident in the current average.

Breaking Down Analyst Ratings: A Detailed Examination

The standing of Fortrea Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Fortrea Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Fortrea Holdings analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Fortrea Holdings: A Closer Look

Fortrea Holdings: Financial Performance Dissected

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Fortrea Holdings's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -8.65%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Fortrea Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.89%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Fortrea Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -9.07%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Fortrea Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.55%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Fortrea Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.82.

The Significance of Analyst Ratings Explained

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Analyst RatingsBZI-AAR
Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 1 8 2 0
Last 30D 0 0 1 0 0
1M Ago 0 0 1 0 0
2M Ago 1 1 4 1 0
3M Ago 0 0 2 1 0
Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Matthew Sykes Goldman Sachs Lowers Neutral $23.00 $26.00
David Windley Jefferies Lowers Hold $21.00 $25.00
Justin Bowers Deutsche Bank Lowers Hold $23.00 $28.00
Charles Rhyee TD Cowen Lowers Hold $23.00 $27.00
Derik De Bruin B of A Securities Lowers Underperform $21.00 $26.00
Patrick Donnelly Citigroup Lowers Buy $30.00 $42.00
Luke Sergott Barclays Lowers Equal-Weight $21.00 $30.00
Elizabeth Anderson Evercore ISI Group Lowers In-Line $22.00 $27.00
Eric Coldwell Baird Lowers Outperform $28.00 $38.00
Elizabeth Anderson Evercore ISI Group Lowers In-Line $27.00 $31.00
Luke Sergott Barclays Announces Equal-Weight $30.00 -
Derik De Bruin B of A Securities Lowers Underperform $26.00 $27.00
  • Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fortrea Holdings. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fortrea Holdings compared to the broader market.
  • Price Targets: Understanding forecasts, analysts offer estimates for Fortrea Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

FTRE Logo
FTREFortrea Holdings Inc
$11.59-%
Overview
Comments
Loading...